Benegut® Perilla: A Comprehensive Encyclopedic Reference
1. Identity, Nomenclature, and Source Material
1.1 Botanical and Chemical Identity
Benegut® Perilla is a proprietary extract derived from Perilla frutescens, a leafy plant in the mint family (Lamiaceae), traditionally used in East Asian medicine and cuisine. Perilla frutescens is a member of the family Lamiaceae and is an annual edible herbaceous plant, native to Asia. The accepted full taxonomic designation is Perilla frutescens (L.) Britt., with "L." acknowledging Linnaean authorship and "Britt." attributing the modern combination to Nathaniel Lord Britton. Perilla belongs to Kingdom: Plantae; Order: Lamiales; Family: Lamiaceae; Genus: Perilla; Species: P. frutescens. Often mistaken for basil or mint, Perilla displays an annual growth habit, reaching 30–100 cm in height. Its opposite leaves are ovate with serrated margins, varying from green to a deep purple hue.
Benegut® is a patented botanical extract obtained by water extraction of shiso leaves (Perilla frutescens L.), an annual edible herbaceous plant harvested on the island of Hokkaido in Japan. Globally, it is well known as a spice of the Japanese cuisine, where it is named Shiso. Common names in other markets include Japanese Melisse or Japanese Basil (USA, Europe).
In the Chinese pharmacopoeial tradition, the plants of P. frutescens were grouped into two species in the ancient Compendium of Materia Medica: those with green leaves on the upper and lower surfaces were classified as Baisu, and those with red or purple on the lower of the leaves were classified as Zisu.
1.2 Proprietary Standardization
Benegut is a proprietary extract of the herb Perilla frutescens that is standardised to its key active ingredient, Vicenin-2, as well as to rosmarinic acid and a special flavonoid fraction. Benegut® is standardised on a special flavonoid fraction and its key active ingredient Vicenin-2 and on rosmarinic acid, determined by HPLC. Bioactive compounds include: rosmarinic acid ≥ 0.05%, special flavonoids fraction ≥ 0.18%, including Vicenin-2 ≥ 0.007%.
Derived from carefully selected Japanese Hokkaido perilla, it is produced using a proprietary water extraction technology to preserve its high concentrations of active compounds, including Vicenin-2, perilla flavonoids, and rosmarinic acid. Benegut is a water-soluble fine beige powder with neutral taste. Benegut's production facility and manufacturing process comply with the highest international standards of safety, hygiene and quality control: ISO-9001:2008, ISO-22000:2005 and is GMP certified for food supplements.
1.3 Manufacturer and Regulatory Background
Benegut is a proprietary Perilla frutescens leaf extract from Vital Solutions GmbH, developed to improve gastrointestinal discomfort, such as bloating, passage of gas, GI rumbling, feeling of fullness, or abdominal discomfort. The extract was subsequently developed by Fytexia, a French botanical innovator, following Vital Solutions becoming part of the Fytexia Group. The extract is covered by patent EP2599488A1, which concerns "Vicenin-2 and derivatives thereof for use as antispasmodic and/or prokinetic agent." In some territories (including Argentina, Australia, the European Union, New Zealand, Switzerland, Turkey, and Ukraine), the ingredient is marketed under the trademark Nutrigut®.
The European Commission (DG SANCO Health and Consumers) confirms in its Novel Food Catalogue that Perilla frutescens leaves are allowable for use as a food supplement ingredient. The herb does not appear on any negative lists of botanicals for food use in any European Member State. It is on the positive list of botanicals for food use in Belgium and Italy and is FDA GRAS for use in dietary supplements in the United States.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine
Perilla frutescens (L.) Britt. is an annual herb with medicine and food homology of the Labiatae family, and its dried stems, leaves, and seeds have been used as medicinal materials in traditional Chinese medicine (TCM). The earliest historical record of P. frutescens can be traced back to the Western Han Dynasty (202 BCE–220 CE), and it has been cultivated for more than two thousand years in China.
The use of perilla in China can be traced back thousands of years, with its earliest written records found in the Shennong Bencao Jing (The Divine Farmer's Materia Medica). It was traditionally used for treating reversed flow of qi (irregularities in the flow of Qi), cough and asthma, and is named Zisuzi in China. P. frutescens is one of the first medicinal and edible plants published by the Chinese Ministry of Health, and its leaves, stems, and seeds can be used as both medicine and edible food.
It has been used as a natural herbal medicine to recover from different symptoms, such as depression-related disease, asthma, anxiety, tumors, coughs, allergies, intoxication, cold, fever, chills, headache, stuffy nose, and some intestinal disorders.
2.2 Japanese Tradition
By the 8th century, Japanese Buddhist monks cultivated shiso in temple gardens, incorporating it into pickles and digestive remedies. Perilla frutescens leaves are commonly consumed as a tea, spice, salad garnish, and sushi wrap in Asia. In the Tōhoku regions of northeastern Japan, the seeds of a closely related variety (P. frutescens var. frutescens, known as egoma) were incorporated into ceremonial foods, with the belief that eating them prolonged life.
In Korean cuisine, perilla leaves (Korean: 깻잎) are widely used as a herb and a vegetable. Perilla can be used fresh as a ssam vegetable, fresh or blanched as a namul vegetable, or pickled in soy sauce or soybean paste to make pickle or kimchi.
2.3 Traditional Preparations and Their Purposes
Traditional Ayurvedic practice uses primarily the leaves and seeds—leaves for teas and poultices, seeds pressed for oil—while stems are rarely included. An infusion of the plant is useful in the treatment of asthma, colds, cough and lung afflictions, influenza prevention, nausea, vomiting, abdominal pain, constipation, food poisoning and allergic reactions (especially from seafood). The stems are a traditional Chinese remedy for morning sickness and restless fetus in pregnancy.
In Korean traditional medicine, perilla seed oil (deulgireum) was prized for skin conditions as early as the Goryeo period (918–1392 CE). The plant has been cultivated for multiple usages, traditionally for curing depression-related disease, asthma, anxiety, tumors, coughs, allergies, intoxication, cold, fever, chills, headache, stuffy nose, and some intestinal disorders, and as an antioxidant.
3. Key Constituents and Active Compounds
3.1 Overview of Phytochemical Profile
More than 100 compounds have been reported for P. frutescens and most of them are contributed to its medical benefits such as anti-allergic, anti-inflammatory, anti-oxidant, anticancer, anti-microbial, anti-depressive, and anti-cough effects. The Benegut® extract is specifically defined by three categories of active constituents: Vicenin-2, rosmarinic acid, and a broader flavonoid fraction.
3.2 Rosmarinic Acid
Rosmarinic acid (RA) is a naturally occurring polyphenolic ester of caffeic acid and 3,4-dihydroxyphenyllactic acid. Perilla frutescens leaves are rich in rosmarinic acid, which has antioxidant, anti-inflammatory, and anticancer effects. Research has demonstrated that perilla extract downregulates proinflammatory mediators via the inactivation of the NF-κB signaling pathway in LPS-stimulated macrophage cells. Rosmarinic acid inhibits cyclooxygenase-2 (COX-2) protein expression and caspase-1 activity in nasal mucosa tissue, and in activated human mast cells, NF-κB/RelA and caspase-1 activation was inhibited after treatment with perilla extract or rosmarinic acid.
Both perilla seed oil and rosmarinic acid-rich fractions significantly decreased the generation of reactive oxygen species (ROS). The mRNA expression levels of IL-1β, IL-6, IL-8, TNF-α, and COX-2 were significantly decreased by rosmarinic acid treatment. The expression of MnSOD, FOXO1, and NF-κB and phosphorylation of JNK were also significantly diminished.
3.3 Vicenin-2
Vicenin-2 is a bis-C-glycosylflavonoid (specifically, apigenin-6,8-di-C-glucoside) and is considered the key marker compound of the Benegut® extract. Vicenin-2, a bis-C-glycosylflavonoid, displayed no direct spasmolytic effect, but significantly reduced Ba²⁺- or acetylcholine-induced smooth muscle contractions in the rat ileum, demonstrating an antispasmodic effect. Benegut® and isolated Vicenin-2 significantly decreased acetylcholine- or Ba²⁺-induced rat ileum contractions, indicating an antispasmodic effect. The antispasmodic action of Vicenin-2 is patented (EP2599488A1).
3.4 Additional Flavonoid Constituents
The leaves, stems, fruits, and seeds of P. frutescens constitute different types of flavonoids, including flavones, flavanones, chalcones, and aurones. P. frutescens leaves contain flavones such as luteolin, apigenin, scutellarein, negletein, vicenin-2, and catechin, along with several derivatives of luteolin, apigenin, and scutellarein, including luteolin-7-O-glucuronide, luteolin-7-O-diglucuronide, apigenin-7-O-glucuronide, apigenin-7-O-diglucuronide, and apigenin-7-O-glucoside.
The complete fingerprint of the Benegut® extract as characterized by RP-HPLC reveals a defined polyphenolic profile. The extract comprises approximately 10 different flavonoids, caffeic acid, and rosmarinic acid.
3.5 Anti-Allergic Compounds
Different bioactive components of P. frutescens, including rosmarinic acid, caffeic acid, luteolin, apigenin, methoxyflavanone, and α-linolenic acid, were found to possess anti-allergic activity. Perilla-derived methoxyflavanone (PDMF) may be used to prevent IgE-driven type I hypersensitivity reactions. Akt phosphorylation and intracellular Ca²⁺ influx, the two critical molecular events involved in mast cell degranulation in allergic reactions, are suppressed by PDMF.
4. Established Mechanisms of Action
4.1 Prokinetic and Antispasmodic Activity
Benegut uniquely combines prokinetic and antispasmodic as well as anti-inflammatory effects, leading to an immediate, perceptible relief of gastrointestinal discomfort. The prokinetic and antispasmodic mechanisms of action have been characterized in both in vitro and ex vivo models. From previous mechanistic studies, Perilla frutescens extract has been shown to improve the intestinal barrier function measured with transepithelial electrical resistance in a cell culture model. The antispasmodic effect of vicenin-2 has also been demonstrated in an ex vivo study and is patented.
4.2 Intestinal Barrier (Tight Junction) Reinforcement
Benegut® contributes to the reinforcement of tight junctions of cells. The effect of Benegut® on TNFα-caused tight junction leakage was investigated on intestinal epithelial cells (Caco-2). Benegut® showed a significant restorative effect on the tight junctions, after 6 hours until 24h against TNF-α treatment. Studies indicated that Benegut® perilla moderates TNF-α, IFN-γ, and IL-4 to support cytokine balance and GI epithelial tight junction integrity. This in vitro work was published by Buchwald-Werner et al. in Agro Food Industry Hi Tech (2016; vol. 27(5)).
4.3 Gut–Brain Axis Modulation
In vitro, ex vivo, and human studies demonstrated that Benegut is able to balance bowel movement by interacting with the neurological system and therefore can counteract the effects of psychosocial factors, such as stress causing altered gut physiology leading to gastrointestinal discomfort. Recent studies have identified a link between the body and mind, called the gut–brain axis. Psychosocial factors, such as daily stress, may cause altered gut physiology leading to ileum contractions and consequently gastrointestinal symptoms.
4.4 Anti-Inflammatory Pathway Inhibition
Evidence shows that Perilla frutescens extract attenuates dextran sulfate sodium (DSS)-induced colitis through generating anti-inflammatory cytokines, suppressing proinflammatory cytokines, and inactivating both NF-κB and STAT3 pathways. In silico PPAR docking simulations demonstrated the potential of perilla flavonoids as PPAR agonists, and perilla water extract and isolated compounds suppressed LPS-induced upregulation of Il6, Mcp1, and Tnfa in macrophage cells, which may be mediated through the PPAR/NF-κB signaling pathway.
4.5 Prebiotic Activity
A proprietary Perilla frutescens leaf extract was used to investigate prebiotic effects on strains of Lactobacillus, Bifidobacterium, and pathogenic bacteria by testing for growth stimulation effects on agar plates. Perilla frutescens leaf extract was confirmed to be a prebiotic, supporting the growth of selected lactobacilli and bifidobacteria and inhibiting the growth of pathogenic bacteria. It has proven prebiotic effects, particularly to support growth of L. plantarum, B. lactis, B. longum infantis, and B. longum longum.
5. Scientific Evidence by Area of Use
5.1 Functional Gastrointestinal Discomfort — Chronic Use
Human Clinical Evidence
The foundational clinical study for Benegut® was published in a peer-reviewed journal in 2014. Vital Solutions and Amino Up Chemical Co. Ltd. published a study focused on the ingredient Benegut, a proprietary Perilla frutescens leaf extract found to improve gastrointestinal discomfort. The study was published in BMC Complementary and Alternative Medicine.
In the double-blind, randomized, placebo-controlled, parallel design human study, 50 healthy people, ages 30–70, were administered capsules containing 150 mg of proprietary Perilla frutescens leaf extract twice a day for 4 weeks. Eighty percent of volunteers taking Benegut reported substantial improvement of gastrointestinal discomfort. "Benegut supplementation showed physiological relevant and statistically significant improvement of gastrointestinal discomfort," said Dr. Sybille Buchwald-Werner, managing director at Vital Solutions.
After 4 weeks of supplementation, all assessed criteria related to digestive comfort showed statistically significant changes following Benegut® consumption. The full study citation is: Buchwald-Werner S, Fujii H, Reule C, Schoen C. Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study. BMC Complement Altern Med. 2014 May 27;14:173.
Evidence Strength and Limitations
The 2014 Buchwald-Werner study is a double-blind, randomized, placebo-controlled trial, which represents a high-quality study design. However, its evidential strength is tempered by important limitations: the sample size of 50 participants is modest; the participants were categorized as "healthy volunteers" (with self-reported GI discomfort) rather than formally diagnosed IBS patients; and the study was conducted in a pilot (exploratory) format. All authors had affiliations with the commercial producers of the extract, representing a potential conflict of interest noted in the publication itself. Nonetheless, the study was published in a peer-reviewed open-access journal and is indexed on PubMed (PMC4038823), providing a meaningful starting point for evidence in this population.
5.2 Acute Postprandial Gastrointestinal Comfort
Human Clinical Evidence
Fytexia announced the results of a clinical study conducted on its Benegut ingredient, which is a patented Perilla frutescens extract standardized in rosmarinic acid and flavonoids, including vicenin-2. In the double-blind, randomized, placebo-controlled cross-over design study, 30 healthy participants between the ages of 25 and 70 were given a high caloric meal and screened over 90 minutes to evaluate gastrointestinal symptoms. Subjects were included if their overall GI discomfort was above 5 out of 10 on a visual analogue scale (VAS). Individual symptoms assessed included feeling of fullness, burping, bloating, heartburn, rumbling, passage of gas, GI discomfort/cramps/pains, nausea, and urge to defecate. Following a 7-day washout period, subjects underwent the same protocol twice with either placebo or supplementation with Benegut (300 mg).
Following supplementation with Benegut®, statistically significant changes in overall gastrointestinal comfort were observed 90 minutes after a high-caloric meal, compared with control conditions. Feeling of fullness, bloating, and burping were the three main endpoints contributing to the observed changes in gastrointestinal comfort.
Fytexia explained that while a previous study demonstrated similar benefits following chronic consumption of Benegut, this study showed benefits following first intake. The study was performed as a double-blind, randomized, placebo-controlled cross-over design with at least a 7-day washout phase between visits. The study was conducted between November 2022 and March 2023.
The clinical trial was registered on ClinicalTrials.gov (NCT05603416) under the sponsor Vital Solutions GmbH. Competing interests were disclosed: Biotesys (CRO) was paid by Amino Up and Vital Solutions (now a part of Fytexia Group) to perform and report the scientific work that formed the basis of this publication. As of the time of this writing, the full manuscript was posted as a preprint on Research Square (rs-6886069/v1) and described as pending publication.
Evidence Strength
The acute crossover study enrolls a small sample (n=30, of whom 22 were women and 8 were men), which limits statistical power and generalizability across sexes. The crossover design is appropriate for within-individual comparisons, and the 90-minute measurement window following a single dose directly demonstrates acute pharmacodynamic effects. As with the 2014 chronic study, the research was sponsor-funded and conducted by authors with commercial relationships with the ingredient's manufacturer, and the manuscript had not yet undergone final peer-reviewed publication at the time sources were available. Independent replication remains absent.
5.3 Irritable Bowel Syndrome (IBS) and Functional GI Disorders
A study published in the BMC Complementary and Alternative Medicine Journal identifies a number of benefits and improved function, achieved in people with IBS (a functional loss of tolerance in the GI tract) when consuming a 300 mg daily dose of perilla extract. The mechanistic plausibility for IBS benefit derives from the combined antispasmodic, prokinetic, anti-inflammatory, and barrier-protective actions of the extract's constituents. Polyphenols might be applicable for preventing IBS and improving IBS symptoms, mainly through suppressing inflammatory signaling pathways, which are known as a novel platform for IBS management. It is important to note that the pivotal 2014 study enrolled "healthy" adults with mild GI complaints rather than subjects meeting formal Rome criteria for IBS, so direct extrapolation to a clinical IBS diagnosis should be made cautiously.
5.4 Intestinal Barrier Function and Permeability
Mechanistic in vitro evidence exists at the cellular level. The effect of Benegut® on TNFα-caused tight junction leakage was investigated on intestinal epithelial cells (Caco-2). Benegut® showed a significant restorative effect on the tight junctions after 6 hours until 24 hours against TNF-α treatment. This was published by Buchwald-Werner et al. in Agro Food Industry Hi Tech (2016; vol. 27(5)). These findings are entirely in vitro and their clinical relevance in humans has not yet been demonstrated in a dedicated human intestinal permeability study.
5.5 Gut Microbiota (Prebiotic Effects)
An in vitro study authored by researchers from Vital Solutions GmbH, Amino Up Co. Ltd., and Novozymes Berlin GmbH investigated prebiotic activity. A proprietary Perilla frutescens leaf extract was used to investigate prebiotic effects on strains of Lactobacillus, Bifidobacterium, and pathogenic bacteria by testing for growth stimulation effects on agar plates. Perilla frutescens leaf extract was confirmed to be a prebiotic, supporting the growth of selected lactobacilli and bifidobacteria and inhibiting the growth of pathogenic bacteria. Results underline beneficial effects in applications in blends with probiotics for preventing inflammation and supporting the immune system.
These findings were published in a peer-reviewed trade and science journal (Agro Food Industry Hi Tech) but represent only agar-plate growth assays. No controlled human or animal studies of Benegut's effect on the gut microbiome in living subjects have been published in the peer-reviewed literature at the time of source retrieval. Clinical studies have demonstrated that Benegut® helps maintain 60–82% of gastrointestinal function and increases beneficial gut bacteria; however, this specific numerical claim originates from manufacturer-associated promotional literature rather than a stand-alone peer-reviewed publication and should be interpreted accordingly.
5.6 Gastric Ulcer and Mucosal Protection
While not specific to the Benegut® proprietary form, broader evidence from P. frutescens and its constituent rosmarinic acid informs mechanistic plausibility. In a rat model of indomethacin-induced gastric ulcer, pretreatment with an aqueous fraction of perilla leaf extract rich in rosmarinic acid reduced ulcer index, decreased gastric secretion volume and acidity, and elevated gastric pH. In histopathological examination, the extracts decreased mucosal ulcer, inflammatory infiltration, and degenerative lining cells. The experiment showed preservation of mucus and apoptosis protection of the extracts on gastric mucosal ulcer. The findings demonstrated that these extracts were capable of protecting the stomach against gastric ulcers induced by indomethacin through anti-inflammatory and antiapoptotic mechanisms. These findings are preclinical (animal model) and cannot be directly extrapolated to human outcomes.
5.7 Anti-Allergic and Respiratory Effects
These effects are associated with Perilla frutescens extracts and constituents more broadly, and not with Benegut® specifically, which is positioned and studied primarily for GI use. Increased levels of IgE in the serum and tissues of sensitized mice were reduced by perilla extract or rosmarinic acid administration. The histamine level was also reduced. Protein levels and mRNA expressions of IL-1β, IL-6, and TNF-α were inhibited. Mast cell and eosinophil infiltration increases caused by sensitization were decreased. These are animal and in vitro data; clinical human evidence specifically for the Benegut® extract in allergic conditions is not available in the published literature.
6. Body Systems and Health Areas
Benegut® is a patented botanical extract from shiso leaves (Perilla frutescens), developed to support digestive comfort. It contributes to normal gastrointestinal function and intestinal barrier integrity, helping to improve overall intestinal comfort.
- Gastrointestinal System: Reduces symptoms of functional gastrointestinal disorders such as bloating, gas, discomfort, and altered bowel habits; provides anti-inflammatory and antispasmodic effects in the digestive tract.
- Gut–Brain Axis: Modulates the gut–brain axis, helping to relieve digestive symptoms related to stress and anxiety.
- Intestinal Immune/Barrier Function: The Caco-2 cell model demonstrates restoration of intestinal tight junctions disrupted by TNF-α, indicating relevance to gut epithelial immunity and permeability.
- Gut Microbiome: Due to its proven prebiotic effects, it is an ideal candidate for blends with probiotic and/or other prebiotic ingredients.
- Inflammatory Pathways: Rosmarinic acid and flavonoid constituents have been shown to suppress NF-κB and STAT3 signaling in multiple cell-line models, suggesting relevance to systemic inflammatory processes.
P. frutescens showed strong anti-inflammatory, antidepressant, anti-spasmodic, anticancer, antioxidant, antimicrobial, insecticidal, neuroprotective, and hepatoprotective effects in preclinical studies; however, only the gastrointestinal effects have been evaluated in published human clinical trials for the Benegut® form.
7. Dosage Forms and Reported Dosages
Benegut is an IP-protected, natural ingredient approved for use in food supplements in Europe and the USA. It is a water-soluble fine beige powder with a recommended daily dosage of 300 mg. Benegut is obtained by water extraction of Perilla frutescens (L.) leaves.
The following dosages have been used in published or registered studies specific to Benegut®:
- Chronic GI discomfort study (2014, BMC Complement Altern Med): 50 healthy people, ages 30–70, were administered capsules containing 150 mg of proprietary Perilla frutescens leaf extract twice a day (= 300 mg/day total), for 4 weeks.
- Acute postprandial study (2022–2023, NCT05603416): Participants consumed 300 mg of Benegut® or placebo after a high caloric meal as a single dose.
- Recommended daily dosage as stated by manufacturer: The recommended daily dosage is 300 mg.
The 300 mg/day dose is consistent across both the chronic divided-dose regimen (2 × 150 mg) and the single acute dose format. In the acute study, the study product was composed of filler sorbitol, Benegut® (15.0%, 300 mg per portion), aroma (1.5%), and excipients, and was provided as a direct-dissolve preparation in sticks ingested orally directly after the end of a high caloric meal as a single dose.
This specialized extract is standardized for flavonoids and rosmarinic acid, which are key bioactive compounds responsible for its effects on the gut–brain axis, digestive comfort, and inflammation regulation. Benegut® is also described as suitable for incorporation into capsules, tablets, and sachet formats. No pediatric dosage data have been published.
8. Safety Considerations and Interactions
8.1 General Tolerability
No adverse event linked to Benegut® supplementation has been recorded based on the clinical trials conducted by the manufacturer. This is supported by the 2014 randomized controlled trial, in which Benegut was described as well tolerated over the 4-week study period in 50 participants.
Although a well-established application of products from any herb including perilla requires proofs not only for efficacy but also for safety, there are only very few studies that have been reported about the toxicological aspects of materials originating from perilla. This limits the ability to characterize the full safety profile from independent evidence.
8.2 Allergy and Hypersensitivity
Inhaling smoke from roasting perilla seeds led to occupational asthma through an IgE-mediated mechanism. Additionally, a single case of anaphylaxis caused by perilla seed was also reported. These reports concern perilla seed exposure via inhalation or ingestion in the raw food context; the Benegut® extract is derived from leaves via water extraction, and the allergenic potential of this specific preparation has not been separately characterized.
Rare cases of contact dermatitis in individuals sensitive to plants of the Lamiaceae family have been documented when handling fresh leaves.
8.3 Pregnancy and Lactation
Benegut is not recommended for use during pregnancy or while breastfeeding according to the manufacturer's guidance. Its safety profile remains largely untested in certain populations, including young children and pregnant or nursing women.
8.4 Potential Drug Interactions
No pharmacokinetic drug interaction studies have been published for the Benegut® extract specifically. At the level of constituent phytochemistry, the high alpha-linolenic acid content associated with perilla preparations might potentiate anticoagulant medications — a consideration relevant to preparations containing perilla seed fractions rather than the leaf extract used in Benegut®. Rosmarinic acid, as a polyphenol, has the theoretical potential to interfere with cytochrome P450 enzymes or drug absorption, though no documented interactions specific to Benegut® appear in the published peer-reviewed literature.
8.5 Pulmonary Toxicant Ketones (PKs)
Perilla ketones (PKs) have a certain degree of pulmonary toxicity. Although only a few people have allergic reactions to the seeds of P. frutescens, it is recommended to limit the intake of PK-type P. frutescens when eating food containing the P. frutescens seeds. Benegut® is a leaf extract prepared by water extraction; the relevance of perilla ketone toxicity to this specific extract formulation is not addressed in published safety data and is primarily a concern with seed-derived preparations of certain botanical varieties.
8.6 Regulatory Quality Indicators
Benegut® is Non-GMO, Halal, Kosher, gluten-free, and suitable for vegetarians. The production facility complies with ISO-9001:2008, ISO-22000:2005, and is GMP certified for food supplements.
9. Summary of Evidence Assessment
The totality of the evidence for Benegut® Perilla can be summarized across three tiers:
- Mechanistic (in vitro/ex vivo): Reasonably well-characterized. Studies using Caco-2 intestinal epithelial cells, isolated rat ileum smooth muscle, and cell-free antioxidant assays support antispasmodic, tight-junction-protective, anti-inflammatory (NF-κB inhibition), and prebiotic mechanisms. These findings are published in peer-reviewed contexts, though many were funded by the manufacturer.
- Clinical Human Evidence: Limited but present. Two randomized, double-blind, placebo-controlled human trials have been conducted — one chronic (4 weeks, n=50, published 2014 in BMC Complement Altern Med) and one acute crossover (n=30, conducted 2022–2023, registered on ClinicalTrials.gov, preprint available). Both demonstrate statistically significant improvements in GI discomfort endpoints. Both were sponsored by the ingredient's manufacturer, a relevant limitation. Sample sizes are small, and no independent replication exists to date.
- Broader Perilla frutescens research: A substantial body of preclinical literature (animal models and cell culture) supports anti-allergic, anti-inflammatory, gastroprotective, and antimicrobial properties of P. frutescens constituents — particularly rosmarinic acid — but these findings are not specific to the Benegut® extract and cannot be directly attributed to it.
Overall, Benegut® Perilla occupies a category of botanical ingredients with promising but early-stage human evidence, strong mechanistic underpinning, a well-characterized phytochemical identity, and an established long-term traditional safety record as a food ingredient.
References
Go back